The global Immunotherapy Drugs Market size was estimated at USD 101,899.8 million in 2023 and is projected to reach USD 284,533.4 million in 2030 at a CAGR of 15.8 % during the forecast period 2024-2030.
Immunotherapy drugs are a class of treatments designed to enhance or suppress the body’s immune system to fight diseases, particularly cancer. Unlike traditional therapies such as chemotherapy or radiation, which target the disease directly, immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells, or by blocking mechanisms that allow tumours to evade immune responses.
Get Free Sample Report@ https://www.delvens.com/get-free-sample/immunotherapy-drugs-market
This category includes checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and immune cell therapy, all of which have been pivotal in treating various types of cancers, such as melanoma, lung cancer, and lymphoma. The increasing adoption of these therapies has transformed cancer treatment paradigms, leading to significant advancements in oncology.
The scope of the immunotherapy drugs market is vast, encompassing a wide range of therapeutic areas, including oncology, autoimmune disorders, infectious diseases, and more. While oncology remains the dominant segment, growing interest in autoimmune conditions, such as rheumatoid arthritis and psoriasis, is contributing to the expansion of the market.
Recent Developments
- In May 2024, Merck made a strategic move by acquiring EyeBio, a UK-based biotechnology firm focused on ophthalmology. As part of the acquisition, Merck gained rights to EyeBio’s investigational candidate, Restoret (EYE103), a tri-specific antibody designed to act as an agonist of the WNT signaling pathway. This innovative therapy has the potential to impact the treatment of eye diseases, broadening Merck's portfolio beyond oncology and into ophthalmology, further enhancing its position in the biopharmaceutical market.
- In December 2023, F. Hoffmann-La Roche expanded its therapeutic capabilities in gastrointestinal health through the acquisition of Telavant Holdings, Inc., a company jointly owned by Roivant Sciences and Pfizer. This acquisition aims to strengthen Roche’s portfolio by advancing the development of innovative therapies targeting gastrointestinal disorders. By integrating Telavant's pipeline, Roche is positioning itself to play a critical role in addressing unmet medical needs in gastrointestinal healthcare, aligning with its broader strategic focus on expanding its presence in specialty medicine.
- In May 2023, Janssen Global Services, a subsidiary of Johnson & Johnson, entered into a collaboration with Cellular Biomedicine Group Inc. (CBMG) to advance chimeric antigen receptor (CAR) T-cell therapies. This partnership is focused on developing and commercializing CAR T-cell therapies for B-cell malignancies, a class of blood cancers. By leveraging CBMG’s expertise in cell therapy and Janssen's resources in oncology, the collaboration aims to enhance the efficacy and accessibility of CAR T-cell treatments, marking a significant step in the evolution of immunotherapy-based cancer treatments.
Prominent Players
· Merck & Co., Inc.
· Johnson & Johnson Services, Inc.
· F. Hoffman-La Roche Ltd.
· Pfizer Inc.
· AstraZeneca
· Novartis AG
· Amgen Inc.
· Gilead Sciences, Inc.
· Bristol-Myers Squibb Company
· Eli Lilly and Company
· Sanofi
· Takeda Pharmaceutical Company Limited
For More Inquiry@ https://www.delvens.com/Inquire-before-buying/immunotherapy-drugs-market
North America to Dominate the Market
North America led the global immunotherapy drugs market in 2021, capturing over 44.90% of the total revenue. The region's growth is expected to continue, driven by the approval and launch of new immunotherapy treatments and favourable reimbursement policies. For example, in October 2021, Merck’s Keytruda, an anti-PD-1 therapy, received FDA approval in combination with chemotherapy for cervical cancer. Additionally, in August 2021, Bristol Myers Squibb's OPDIVO (nivolumab) was approved by the FDA for treating urothelial carcinoma.
The Immunotherapy Drugs Market Segmentation:
By Type
· Antibody Drugs
· Inhibitor Drugs
· Interferons and Interleukins
· Cancer Vaccines
· Other Types
By Application
· Cancer
· Autoimmune and Inflammatory Diseases
· Haematology
· Osteology
· Neurology
· Other Applications
By Route of Administration
· Intravenous
· Subcutaneous
· Other Routes of Administration
By End User
· Hospitals
· Long-Term Care Facilities
· Other End Users
Based on region:
· Asia Pacific
· North America
· Europe
· South America
· Middle East & Africa
Get Detailed Report@ https://www.delvens.com/report/immunotherapy-drugs-market
Frequently Asked Questions
· What are the years considered to study Immunotherapy Drugs Market intelligence report?
· What is the compound annual growth rate (CAGR) of the Immunotherapy Drugs Market?
· Which region holds the largest market share in Immunotherapy Drugs Market?
· Which region is the fastest growing in Immunotherapy Drugs Market?
· Who are the major players in Immunotherapy Drugs Market?
In addition to the market data for the Immunotherapy Drugs Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
More Related Reports:
Plastic Surgery and Integumentary System Market
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
Unit No. 01, 3rd Floor, Plot No. 56, Block B
Sector 2 Noida, Near Noida Sector 15 Metro Station 201301, IN
+44 20 3290 6466
+0120- 4903958
Comments
0 comment